A cell permeable bimane-constrained PCNA-interacting peptide
Related Experiment Video
Updated: Oct 15, 2025

Biotinylated Cell-penetrating Peptides to Study Intracellular Protein-protein Interactions
Published on: December 20, 2017
Aimee J Horsfall1,2,3, Beth A Vandborg1,4, Zoya Kikhtyak5
1Institute of Photonics and Advanced Sensing (IPAS), The University of Adelaide Adelaide South Australia 5005 Australia john.bruning@adelaide.edu.au andrew.abell@adelaide.edu.au.
Abstract:
The human sliding clamp protein known as proliferating cell nuclear antigen (PCNA) orchestrates DNA-replication and -repair and as such is an ideal therapeutic target for proliferative diseases, including cancer. Peptides derived from the human p21 protein bind PCNA with high affinity via a 310-helical binding conformation and are known to shut down DNA-replication. Here, we present studies on short analogues of p21 peptides (143-151) conformationally constrained with a covalent linker between i, i + 4 separated cysteine residues at positions 145 and 149 to access peptidomimetics that target PCNA. The resulting macrocycles bind PCNA with K D values ranging from 570 nM to 3.86 μM, with the bimane-constrained peptide 7 proving the most potent. Subsequent X-ray crystallography and computational modelling studies of the macrocyclic peptides bound to PCNA indicated only the high-affinity peptide 7 adopted the classical 310-helical binding conformation. This suggests the 310-helical conformation is critical to high affinity PCNA binding, however NMR secondary shift analysis of peptide 7 revealed this secondary structure was not well-defined in solution. Peptide 7 is cell permeable and localised to the cell cytosol of breast cancer cells (MDA-MB-468), revealed by confocal microscopy showing blue fluorescence of the bimane linker. The inherent fluorescence of the bimane moiety present in peptide 7 allowed it to be directly imaged in the cell uptake assay, without attachment of an auxiliary fluorescent tag. This highlights a significant benefit of using a bimane constraint to access conformationally constrained macrocyclic peptides. This study identifies a small peptidomimetic that binds PCNA with higher affinity than previous reported p21 macrocycles, and is cell permeable, providing a significant advance toward development of a PCNA inhibitor for therapeutic applications.
Insights
Researchers developed a novel, cell-permeable peptidomimetic that targets proliferating cell nuclear antigen (PCNA). This molecule shows high affinity for PCNA, offering a promising avenue for developing new cancer therapies.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Molecular Biology
Background:
- Proliferating cell nuclear antigen (PCNA) is crucial for DNA replication and repair, making it a key therapeutic target for cancers.
- Peptides from human p21 protein bind PCNA with high affinity, inhibiting DNA replication via a 310-helical conformation.
Purpose of the Study:
- To design and synthesize conformationally constrained peptidomimetics targeting PCNA.
- To evaluate the binding affinity, structural basis, and cellular activity of these novel PCNA inhibitors.
Main Methods:
- Synthesis of macrocyclic peptides with covalent linkers between cysteine residues.
- Binding affinity assessment using KD values.
- Structural analysis via X-ray crystallography and computational modeling.
- Cell permeability and localization studies using confocal microscopy.
Main Results:
- Macrocyclic peptides bound PCNA with KD values from 570 nM to 3.86 μM.
- The bimane-constrained peptide 7 exhibited the highest affinity and adopted the critical 310-helical conformation.
- Peptide 7 demonstrated cell permeability and localized to the cytosol of breast cancer cells.
- The bimane linker provided inherent fluorescence for direct imaging.
Conclusions:
- Conformational constraint, particularly the 310-helical structure, is vital for high-affinity PCNA binding.
- Peptide 7 represents a potent, cell-permeable peptidomimetic inhibitor of PCNA.
- This study advances the development of therapeutic PCNA inhibitors for proliferative diseases.

